Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 5/20 | 0.60 |
| ▸ | CNR2 | P34972 | 2/20 | 0.60 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
| ▸ | PDE2A | O00408 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.35 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | SMO | Q99835 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | KLRK1 | P26718 | 1/20 | 0.34 |
| ▸ | MICA | Q29983 | 1/20 | 0.34 |
| ▸ | RAET1L | Q5VY80 | 1/20 | 0.34 |
| ▸ | CCR5 | P51681 | 1/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14545727 | 0.92 | CNR1 (0.68) | CNR1CNR2USP30PDE2ACYP11B2 | |
| SCHEMBL14545731 | 0.89 | CNR1 (0.66) | CNR1CNR2USP30PDE2ACYP11B2 | |
| SCHEMBL14545486 | 0.83 | CNR1 (0.87) | CNR1CNR2PDE2AEPHX2 | |
| SCHEMBL14545499 | 0.81 | CNR1 (0.53) | CNR1CNR2CACNA1BSMODPP4 | |
| SCHEMBL14545110 | 0.81 | CNR1 (0.52) | CNR1CNR2USP30CYP11B2CACNA1B | |
| SCHEMBL14545109 | 0.80 | CNR1 (0.52) | CNR1CNR2USP30PDE2ACACNA1B | |
| SCHEMBL14545730 | 0.80 | CNR1 (0.50) | CNR1CNR2USP30SMOCCR5 | |
| SCHEMBL14545729 | 0.79 | CNR1 (0.49) | CNR1CNR2USP30CACNA1BSMO | |
| SCHEMBL14545450 | 0.79 | CNR1 (0.55) | CNR1CNR2CYP11B2SMODPP4 | |
| SCHEMBL14545452 | 0.78 | CNR1 (0.55) | CNR1CNR2CYP11B2EPHX2SMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070078135-A1 | Substituted heteroaryl CB1 antagonists | NEUROGEN CORPORATION (US) | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078135-A1 | Substituted heteroaryl CB1 antagonists | CNR1, CNR2, OPRL1 | CNR1 1/4885CNR2 2/4885USP30 2526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.